Investigating the Bioavailability of Broccoli Extract Supplements
2026年8月4日 更新者：Emily Ho、Oregon State University
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
Participants will:
- consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
- complete 3 separate 24 hour study cycles
- submit blood and urine samples for 24 hours
- follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)
研究概览
地位
招聘中
条件
详细说明
This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating.
The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables.
Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
The amount of glucoraphanin that subjects will take will range from 35-70 mg.
Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).
研究类型
介入性
注册 (估计的)
12
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Emily Ho, PhD
- 电话号码：541-737-9559
- 邮箱：emily.ho@oregonstate.edu
研究联系人备份
- 姓名：Sandra Uesugi, RN, BSN, MS
- 电话号码：541-737-3594
- 邮箱：sandra.uesugi@oregonstate.edu
学习地点
-
-
Oregon
-
Corvallis、Oregon、美国、97331
- 招聘中
- Oregon State University
-
接触：
- Sandra Uesugi, RN, BSN, MS
- 电话号码：541-737-3594
- 邮箱：sandra.uesugi@oregonstate.edu
-
首席研究员：
- Emily Ho, PhD
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
是的
描述
Inclusion Criteria:
- Healthy adults, 18-60 years of age
- Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
- Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
- Must be able to give written informed consent
Exclusion Criteria:
- Body Mass Index (BMI) <18.5 or >30.0 kg/m2
- Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
- Pregnancy, breastfeeding, or planning to become pregnant before completing the study
- Engaging in vigorous exercise more than 7 hours per week
- Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
- Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
- Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
- Allergic to broccoli, moringa, mustard, or maitake mushrooms
- Weighs less than 110 pounds
- Diagnosis of sickle cell disease
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：基础科学
- 分配：随机化
- 介入模型：交叉作业
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：35 mg glucoraphanin
Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating.
|
Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
|
|
有源比较器：60 mg glucoraphanin
Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each)
|
Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)
|
|
有源比较器：70 mg glucoraphanin
Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each)
|
Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Urine sulforaphane
大体时间：0, 2, 4, 8, and 24 hours
|
Change from baseline levels of sulforaphane in urine
|
0, 2, 4, 8, and 24 hours
|
|
Urine sulforaphane metabolites
大体时间：0, 2, 4, 8, and 24 hours
|
Change from baseline levels of sulforaphane in urine
|
0, 2, 4, 8, and 24 hours
|
|
Plasma glucoraphanin
大体时间：0, 1, 2, 4, 8, and 24 hours
|
Change from baseline levels of plasma glucoraphanin
|
0, 1, 2, 4, 8, and 24 hours
|
|
Plasma sulforaphane
大体时间：0, 1, 2, 4, 8, and 24 hours
|
Change from baseline levels of plasma sulforaphane
|
0, 1, 2, 4, 8, and 24 hours
|
|
Plasma sulforaphane metabolites
大体时间：0, 1, 2, 4, 8, and 24 hours
|
Change from baseline levels of plasma sulforaphane metabolites
|
0, 1, 2, 4, 8, and 24 hours
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Emily Ho, PhD、Oregon State University
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年8月4日
初级完成 (估计的)
2027年9月1日
研究完成 (估计的)
2028年9月1日
研究注册日期
首次提交
2026年4月27日
首先提交符合 QC 标准的
2026年4月27日
首次发布 (实际的)
2026年5月4日
研究记录更新
最后更新发布 (实际的)
2026年8月7日
上次提交的符合 QC 标准的更新
2026年8月4日
最后验证
2026年8月1日
更多信息
与本研究相关的术语
其他研究编号
- LPI-2026-2211
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
不
IPD 计划说明
We will not share IPD.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.